Neuroleptic Malignant Syndrome — Recognition and Treatment

Key Points

• Stop the causative dopamine antagonist immediately.
• NMS typically evolves over days and features severe generalized rigidity rather than clonus and hyperreflexia.
• CK supports muscle injury assessment but does not confirm or exclude NMS by itself.
• Aggressive supportive care, cooling, hydration, and complication management are the foundation of therapy.
• Benzodiazepines can reduce agitation and rigidity and are especially useful when catatonia overlaps.
• Dantrolene, bromocriptine, or amantadine can be considered in severe disease with expert input.
• Monitor closely for rhabdomyolysis, hyperkalemia, renal failure, aspiration, dysrhythmia, and DIC.
• Future antipsychotic therapy should be restarted only after recovery and with cautious psychiatric planning.

Algorithm

1. Identify recent antipsychotic or dopamine-blocker exposure, dose escalation, depot injection, or abrupt withdrawal of dopaminergic therapy.
2. Stop the suspected drug and assess airway, temperature, rigidity, mental status, hemodynamics, and hydration.
3. Obtain CK, electrolytes, renal and liver tests, CBC, blood gas, urinalysis, ECG, and tests for alternative diagnoses as indicated.
4. Begin IV fluids, active cooling, benzodiazepines, and complication-specific treatment.
5. Use dantrolene or dopaminergic therapy in selected severe or refractory cases with specialist consultation.
6. Admit to monitored care and use ICU support for hyperthermia, major autonomic instability, organ failure, or airway compromise.
7. Trend CK, potassium, creatinine, urine output, and temperature until sustained improvement.
8. Delay antipsychotic rechallenge until full recovery and develop a lower-risk psychiatric medication plan.

Clinical Synopsis & Reasoning

NMS most often follows exposure to antipsychotic dopamine antagonists, particularly after initiation, rapid dose escalation, high-potency parenteral therapy, dehydration, or agitation, but it can occur with many dopamine-blocking antiemetics and other agents. Abrupt withdrawal of levodopa or dopamine agonists can produce a similar syndrome. Onset is usually over one to several days, slower than the typical rapid onset of serotonin syndrome.

Core findings include altered mental status, diffuse lead-pipe rigidity, fever, diaphoresis, tachycardia, labile blood pressure, and laboratory evidence of muscle injury. Reflexes are often normal or reduced rather than hyperreflexic, and clonus is not typical. CK can be markedly elevated, but no single CK threshold defines NMS. Leukocytosis, transaminase elevation, metabolic acidosis, hyperkalemia, and acute kidney injury may occur.

Differential diagnoses include serotonin syndrome, malignant hyperthermia, heat stroke, severe catatonia, anticholinergic or sympathomimetic toxicity, meningitis or encephalitis, sepsis, thyroid storm, and CNS injury. Medication history is therefore central. Evaluate for infection and other causes when features are atypical. Severe catatonia can overlap clinically and may respond to benzodiazepines or electroconvulsive therapy, so psychiatry and neurology input can be valuable.

Treatment Strategy & Disposition

Stop dopamine antagonists immediately and restore withdrawn dopaminergic therapy when NMS followed abrupt cessation and it is safe to do so. Provide IV fluids, external cooling, electrolyte correction, thrombosis prevention, and close urine-output and renal monitoring. Severe rigidity and agitation can respond to benzodiazepines. Intubation may be required for respiratory failure, severe hyperthermia, or inability to protect the airway.

Dantrolene reduces skeletal-muscle calcium release and is used in some severe cases with marked rigidity or hyperthermia. Bromocriptine, a dopamine agonist, or amantadine may be used to restore dopaminergic activity. Evidence is based largely on observational experience rather than large randomized trials, so these agents are generally selected with toxicology, neurology, psychiatry, or critical-care consultation and should not delay supportive care.

Treat rhabdomyolysis, acute kidney injury, hyperkalemia, arrhythmia, aspiration, and DIC when present. Admit suspected NMS, usually to a monitored or ICU setting when hyperthermia, major rigidity, autonomic instability, or organ injury is present. Reintroduction of antipsychotic therapy is delayed until full recovery, then performed cautiously with a lower-risk agent, low starting dose, slow titration, hydration, and psychiatric follow-up.

Epidemiology / Risk Factors

• NMS is rare relative to the widespread use of antipsychotic medications.
• Risk increases with high-potency dopamine blockade, rapid dose escalation, parenteral or depot administration, dehydration, agitation, and prior NMS.
• Both first- and second-generation antipsychotics can cause NMS.
• Dopamine-blocking antiemetics can also trigger the syndrome and may be overlooked during medication review.
• Abrupt withdrawal of Parkinson disease dopaminergic therapy can produce an NMS-like state.

Investigations

Compare with Serotonin Syndrome

Pharmacology

Prognosis / Complications

• Mortality has fallen substantially with early recognition and supportive critical care but remains significant in severe disease.
• Renal failure, severe hyperthermia, respiratory failure, DIC, and delayed diagnosis worsen outcome.
• CK and rigidity usually improve over days after causative-drug withdrawal, although depot medications can prolong recovery.
• Most survivors can later receive necessary psychiatric therapy with careful rechallenge and monitoring.
• A prior episode increases recurrence concern and should remain prominently documented.

Patient Education / Counseling

• Give the patient a clear written record of the suspected causative medication and the diagnosis.
• Do not restart the same antipsychotic or another dopamine blocker independently after discharge.
• Psychiatric follow-up should plan the timing, agent, dose, hydration, and monitoring strategy if antipsychotic therapy remains necessary.
• Patients with Parkinson disease should avoid abrupt interruption of levodopa or dopamine agonists unless directed by a specialist.
• Return urgently for recurrent fever, rigidity, confusion, dark urine, weakness, or autonomic instability after medication changes.
• Families and caregivers should understand that early behavioral change can precede the full syndrome.

Notes

NMS and serotonin syndrome overlap in fever, agitation, and autonomic instability, but the neuromuscular examination and time course often provide the most useful distinction.

The evidence for dantrolene and bromocriptine is less robust than the evidence for immediate drug withdrawal and supportive critical care, so they should be viewed as adjuncts rather than substitutes for resuscitation.

References

1. American Psychiatric Association Practice Guidelines — Link
2. American Heart Association 2025 Special Circumstances of Resuscitation — Link